HPV Vaccination Close to Surgery May Reduce Recurrent Cervical Lesions
(MedPage Today) -- Vaccination for human papillomavirus (HPV) near the time of surgery for precancerous cervical lesions significantly reduced the rate of lesion recurrence, a meta-analysis showed.
Overall, vaccination reduced the risk of recurrent... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 4, 2022 Category: Hematology Source Type: news
HPV vaccine after removal of precancerous cells may cut cervical cancer risk
Study finds reduced risk of cervical cancer recurring after HPV vaccination post-surgery, though further research is neededGiving women the human papillomavirus (HPV) vaccine when precancerous lesions are removed from their cervix may cut the risk of cells recurring and them getting cervical cancer, a study has found.Cases of cervical cancerin the UK have fallen hugely since school pupils aged 13 and 14 – first girls and later boys – began being offered HPV jabs in 2008 as protection against the disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 3, 2022 Category: Science Authors: Denis Campbell Health policy editor Tags: Health Cervical cancer HPV vaccine Vaccines and immunisation Women Women's health UK news Cancer research Medical research Source Type: news
Single Dose of HPV Vaccine Is'Game Changer,' Says WHO Single Dose of HPV Vaccine Is'Game Changer,' Says WHO
The World Health Organization (WHO) says that a single dose of vaccine against human papillomavirus (HPV) delivers solid protection, comparable to that with two-dose schedules.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follic...
Source: Roche Media News - July 21, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andT...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news
Thousands report unusual menstruation patterns after COVID-19 vaccination
Kathryn Clancy got her first dose of a COVID-19 vaccine in early 2021 and 10 days later found herself sitting uncomfortably in a work Zoom meeting during one of the heaviest periods she’d experienced. “I had what’s often called menstrual flooding,” says Clancy, a biological anthropologist at the University of Illinois, Urbana-Champaign. Clancy wouldn’t have thought to connect the experience to the Moderna dose she’d received were it not for her graduate student, Katharine Lee, now at Tulane University, who shared a similar tale. “I had the worst cramps of my life” after COVID-19 vaccination, Lee says. Intri...
Source: ScienceNOW - July 15, 2022 Category: Science Source Type: news
HPV-Related Throat Cancer Outcomes in Men Vary by Race, Ethnicity
FRIDAY, July 15, 2022 -- Non-Hispanic White men are disproportionately affected by late-stage human papillomavirus (HPV)-related oropharyngeal cancer (OPC), but cancer-specific mortality (CSM) is elevated among Hispanic and non-Hispanic Black men,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 15, 2022 Category: Pharmaceuticals Source Type: news
Themis Medi bets big on antiviral drug for Covid
Themis had launched inosine pranobex under brand name Viralex in June this year. Despite the drug not figuring in the government's Covid treatment protocol - the company is banking on the drug to improve overall revenues as it was approved by the Drugs Controller General of India (DCGI) for more indications such as influenza and other viral respiratory diseases (ARDS), mucocutaneous herpes, genital wart and panencephalitis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 11, 2022 Category: Pharmaceuticals Source Type: news
2015 to 2020 Saw Increase in HPV Vaccination Rates Among Teens
FRIDAY, June 24, 2022 -- Human papillomavirus (HPV) vaccination coverage increased among adolescents from 2015 to 2020, with a larger increase seen among boys, according to a study published online June 22 in Pediatrics.
Peng-jun Lu, M.D., Ph.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2022 Category: Pharmaceuticals Source Type: news
HPV Vaccination Rates Continue to Rise
(MedPage Today) -- Overall rates of human papillomavirus (HPV) vaccination among adolescents increased by nearly 20% over a 5-year period, according to survey data.
Among teens ages 13 to 17, overall HPV vaccine coverage increased from 56.1% in... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - June 22, 2022 Category: Infectious Diseases Source Type: news
Reducing sexually transmitted infections [NG221], NICE (published 15th June 2022)
Guideline covers interventions to prevent sexually transmitted infections (STIs) in people from 16yrs age. It aims to reduce the transmission of all STIs, including HIV,& includes ways to help increase uptake of STI testing& vaccines for human papillomavirus& hepatitis A&B. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 16, 2022 Category: Consumer Health News Source Type: news
Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options
Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV).1Nearly nine out of 10 women who die from cervical cancer live in low- and middle-income countries.2For patients living in areas with limited healthcare resources, increasing access to screening and decreasing barriers to sample collection are keys to ultimately preventing this disease.Roche ’s HPV self sampling solution expands access to HPV screening options by enabling patients to privately collect their sample while at a healthcare...
Source: Roche Investor Update - June 16, 2022 Category: Pharmaceuticals Source Type: news
Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options
Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV).1Nearly nine out of 10 women who die from cervical cancer live in low- and middle-income countries.2For patients living in areas with limited healthcare resources, increasing access to screening and decreasing barriers to sample collection are keys to ultimately preventing this disease.Roche ’s HPV self sampling solution expands access to HPV screening options by enabling patients to privately collect their sample while at a healthcare...
Source: Roche Media News - June 16, 2022 Category: Pharmaceuticals Source Type: news
5-Year Interval for Cervical Cancer Screening Safe in HPV-Negative Women
(MedPage Today) -- Women ages 24 to 49 who initially test negative for the human papillomavirus (HPV) can be safely screened for cervical cancer at 5-year intervals, according to results from a U.K. study.
Using data from the first and second... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 3, 2022 Category: Hematology Source Type: news
Increasing Impact of HPV Vaccination Seen in the United States
TUESDAY, May 17, 2022 -- The impact of human papillomavirus (HPV) vaccination is increasing in the United States, with evidence of herd protection, according to a study published online May 17 in the Annals of Internal Medicine.
Hannah G.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 17, 2022 Category: Pharmaceuticals Source Type: news
